Oragenics Inc (OGEN) stock
Close on Nov 13, 2026Market cap $906.90KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $906.90K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.83
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$9.62M
- EPS, diluted
- -$4.56
- Book value per share
- $0.24
- Diluted shares
- 5M
Trading
- Previous close
- $0.35
- Open
- $0.21
- Day's range
- $0.17 – $0.23
- Volume
- 17,476,540
- Average volume (20 days)
- 2,479,777
- Beta (5 years)
- 1.31
- 52-week range
- $0.17 – $1.22
- RSI (14 days)
- 14.3
- Volatility (1 year)
- 78.7%
- Relative volume
- 46.06×
- WACC
- 11.7%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | OGEN | S&P 500 | Difference | OGEN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -55.0% | -3.0% | −52.0 pts | ||
| 3 months | -62.1% | -2.8% | −59.3 pts | ||
| Year to date | -74.3% | +11.5% | −85.8 pts | ||
| 1 year | -82.4% | +13.5% | −95.8 pts | ||
| 3 years | -99.8% | +77.7% | −177.5 pts | -87.7% | +21.1% |
| 5 years | -100.0% | +72.6% | −172.6 pts | -82.2% | +11.5% |
| 10 years | -100.0% | +308.2% | −408.2 pts | -65.4% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Oragenics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- Update
- Update
- Update
About Oragenics
Pharmaceutical Preparations
Oragenics, Inc. is a development-stage biopharmaceutical company focused on the research and development of nasal delivery therapies for neurological conditions and infectious diseases. The company concentrates on advancing its lead product candidate, ONP-002, a synthetic neurosteroid engineered to cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation. Administered through a lightweight, breath-propelled intranasal powder device, the drug candidate targets mild traumatic brain injury, commonly referred to as concussion. As an investigational biopharmaceutical business without commercialized products, the enterprise aims to pursue future distribution and licensing partnerships with industry collaborators and qualified distributors.
Company profile, executives and historyOragenics stock: common questions
What is Oragenics's stock price?
OGEN closed at $0.20 on Nov 13, 2026, down 42.59% on the day. Over the past 52 weeks it traded between $0.17 and $1.22.
What is Oragenics's market cap?
Oragenics was worth $906.90K at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is OGEN's P/E ratio?
Oragenics lost money over fiscal 2025 (diluted EPS -$4.56), so it has no meaningful P/E ratio.
Does Oragenics pay a dividend?
No. Oragenics has not paid a cash dividend over the last twelve months.
How has OGEN stock performed over the past year?
Including dividends, OGEN returned -82.4% over the past year, against +13.5% for the S&P 500.
How many OGEN shares are sold short?
1M shares were sold short at the latest FINRA report, 19.02% of the float, or 40.1 days of average trading volume.
Who are Oragenics's competitors?
Companies most similar to Oragenics by business, industry and size include BIVI, NTHI, MIRA, MNOV, RLMD.
See a number that looks wrong?